Involvement and Mechanism of DGAT2 Upregulation in the Pathogenesis of Alcoholic Fatty Liver Disease

Zhigang Wang \(^1,2\), Tong Yao \(^1\), Zhenyuan Song \(^1\)*

\(^1\)Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL 60612  
\(^2\)College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

**Corresponding author:**  
Zhenyuan Song, Ph. D.  
Department of Kinesiology and Nutrition  
University of Illinois at Chicago  
1919 W Taylor Street, RM506G  
Chicago, IL 60612, USA  
Phone: (312)-996-7892  
Fax: (312)-413-0319  
E-mail: song2008@uic.edu

**Running Title:** DGAT2 upregulation in ALD

**Key Words:** Alcohol, Fatty Liver, ERK1/2, DGAT2, Betaine.

**Abbreviations:** ALD, alcoholic liver disease; ERK1/2, extracellular signal-regulated kinases 1 and 2; DGAT, acyl-CoA:diacylglycerol acyltransferase; TG, triglyceride; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; AFC, N-acetyl-S-farnesyl-L-cysteine; VLDL, very low-density lipoprotein; FAs, fatty acids; DG, diacylglycerol; ALT, alanine aminotransferases; EGF, epidermal growth factor; GSH, glutathione; SREBP-1c, sterol regulatory element binding protein-1c; ICMT, isoprenylcysteine carboxyl methyltransferase.

**Financial Support**

Supported by the National Institutes of Health grants K01 AA015344 and R01 AA017442 (Z Song).
Abstract

The mechanisms involved in the development of alcoholic liver disease (ALD) are not well-established. We investigated the involvement of acyl-CoA: diacylglycerol acyltransferase 2 (DGAT2) upregulation in mediating hepatic fat accumulation induced by chronic alcohol consumption. Chronic alcohol feeding caused fatty liver and increased hepatic DGAT2 gene and protein expression, concomitant with a significant suppression of hepatic MEK/ERK1/2 activation. In vitro studies demonstrated that specific inhibitors of the MEK/ERK1/2 pathway increased DGAT2 gene expression and triglyceride (TG) contents in HepG2 cells, while epidermal growth factor, a strong ERK1/2 activator, had the opposite effect. Moreover, chronic alcohol feeding decreased hepatic S-adenosylmethionine (SAM): S-adenosylhomocysteine (SAH) ratio, an indicator of disrupted transmethylation reactions. Mechanistic investigations revealed that N-acetyl-S-farnesyl-L-cysteine, a potent inhibitor of isoprenylcysteine carboxyl methyltransferase, suppressed ERK1/2 activation, followed by an enhanced DGAT2 expression and an elevated TG content in HepG2 cells. Lastly, we demonstrated that the beneficial effects of betaine supplementation in ALD were associated with improved SAM/SAH ratio, alleviated ERK1/2 inhibition, and attenuated DGAT2 upregulation. In conclusion, our data suggest that upregulation of DGAT2 plays an important role in the pathogenesis of ALD, and that abnormal methionine metabolism contributes, at least partially, to DGAT2 upregulation via suppression of MEK/ERK1/2 activation.
INTRODUCTION

Alcoholic liver disease (ALD) continues to be an important health problem in the United States. Although much progress has been made over the past two decades, the mechanisms involved in its initiation and progression remain to be fully understood. The disease is characterized by early steatosis, subsequent steatohepatitis (steatosis with inflammatory cell infiltration and necrosis), and, in some instances, progression to fibrosis and/or cirrhosis (1, 2). Excessive neutral fat accumulation in hepatocytes (steatosis) is the most common and earliest response of the liver to chronic alcohol consumption (3) and plays a critical role in disease progression. Hepatic steatosis results from an imbalance between intrahepatic triglyceride (TG) production and removal. Both uptake of free fatty acids (FA) to the liver and de novo synthesis contribute to hepatic TG production, while FA beta-oxidation and formation of very low-density lipoprotein (VLDL) particles contribute to hepatic TG removal.

The final step and rate-limiting reaction in TG synthesis is catalyzed by acyl CoA:diacylglycerol acyltransferase (DGAT), which covalently joins a fatty acyl-CoA and a diacylglycerol (DG) molecule to form TG. In mammals, DGAT occurs in two isoforms, DGAT1 and DGAT2, from distinct gene families (4, 5). Although both isoforms are widely expressed and present at high levels in white adipose tissue, DGAT1 is most highly expressed in the small intestine, whereas DGAT2 is primarily expressed in the liver (4, 6). Evidence suggest that the two enzymes play different roles in TG metabolism, with DGAT2 participating in steatosis and DGAT1 in VLDL synthesis. Overexpression of liver-specific DGAT2 in mice results in hepatic steatosis (7). Conversely, inhibition of DGAT2 with antisense oligonucleotides reverses hepatic steatosis in ob/ob mice and in mice challenged with high-fat diet (8-10), suggesting that this enzyme plays a critical role in the development of fatty liver disease. Although strong evidence supports that fatty liver development induced by chronic alcohol consumption is secondary to increased de novo synthesis, the effect of alcohol exposure on DGAT regulation remains to be clarified.
Disrupted methionine metabolism plays a pathological role in ALD (11-15). S-adenosylmethionine (SAM) is the first product in the methionine metabolic pathway and a universal methyl donor. After donating its methyl group for transmethylation reaction, SAM is converted into S-adenosylhomocysteine (SAH), which is subsequently hydrolyzed to homocysteine and adenosine. In turn, SAH is a potent inhibitor of most known methyltransferases. Alcohol-induced abnormal methionine metabolism is characterized by disrupted transmethylation reactions due to decreased SAM and increased SAH levels and affects numerous signaling pathways involved in apoptosis, regeneration, and lipid metabolism. Among these is the Ras/ERK1/2 pathway. The extracellular signal-regulated kinases 1 and 2 (ERK1/2) are members of the mitogen-activated protein kinase (MAPK) family, whose activation results in cell growth, proliferation, survival, and inflammation (16). The activation of ERK1/2 is strongly dependent on the GTPase Ras, whose activity requires association with cellular membranes (17, 18). Ras plasma membrane association requires a series of posttranslational modifications of its carboxyl terminus, including farnesylation, proteolysis, and methylation of its CAAX sequence. The methylation reactions require SAM as a methyl group donor to produce methylated Ras. In this context, ERK1/2 activation is closely related to methionine metabolism.

We previously reported that ERK1/2 phosphorylation reduced in the liver of alcohol-fed rats, and this is associated with hypercholesterolemia and reduced hepatic low-density lipoprotein (LDL) receptor expression, suggesting that the ERK1/2 pathway participates in the regulation of hepatic lipid metabolism (19). In the present study, we conducted in vivo and in vitro experiments to investigate the role of DGAT2 upregulation in the development of hepatic steatosis in alcohol-fed mice and the potential mechanistic involvement of suppression of the MEK/ERK1/2 pathway in DGAT2 upregulation.
MATERIALS AND METHODS

Animals and Treatments
Male C57BL/6 mice weighing 25 ± 0.5 g (means ± SD) were obtained from the Jackson Laboratory (Bar Harbor, ME). Studies were approved by the Institutional Animal Care and Use Committee, which is certified by the American Association of Accreditation of Laboratory Animal Care. Eight mice were randomly assigned to two groups and fed for four weeks with liquid diets containing (in percent of energy intake) 18% protein, 35% fat, 12% carbohydrate, and 35% either ethanol (alcohol-fed, AF) or an isocaloric maltose-dextrin mixture (pair-fed, PF), according to Lieber and De Carli (20). Food intake and body weight were recorded daily and weekly, respectively. For betaine supplementation, betaine (anhydrous; Sigma, St. Louis, MO) was supplemented in the alcohol-containing liquid diet (1%, w/v) and started simultaneously with AF diet. Mice were euthanized and plasma and liver tissue samples harvested at the end of the experiment.

Cells and Culture Conditions
HepG2 cells, a human hepatoma cell line, were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM containing 10% (v/v) fetal bovine serum, 2mM glutamine, 5U/ml penicillin, and 50μg/ml streptomycin at 37 °C in a humidified O₂/CO₂ (19:1) atmosphere.

Plasma Biochemical Assays
Plasma levels of alanine aminotransferases (ALT) and TG were assayed using commercially available kits (Infinity, Thermo Electron, Melbourne, Australia).

Liver TG Measurements
For intrahepatic TG measurement, liver tissues (~80mg) were homogenized in 1.0ml NaCl (50mM) solution and hepatic total lipids were extracted overnight in 10 ml heptane:isopropanol (3:2) mixture at 4°C. Hepatic TG content was determined by enzymatic colorimetric methods using a commercially available kit (Infinity,
Measurement of Methionine Metabolites

Liver tissue was homogenized and deproteinized in 4% metaphosphoric acid (1:8, m/v). The homogenates were centrifuged at 15,000g for 10 minutes. SAM and SAH were determined via a high-performance liquid chromatography (HPLC) method using a 5-mm Hypersil C-18 column (250 × 4.6 mm). The mobile phase consisted of 40mM ammonium phosphate, 8mM heptane sulfonic acid [ion-pairing reagent (pH 5.0)], and 6% acetonitrile, and was delivered at a flow rate of 1.0ml/minute. SAM, SAH, betaine and GSH were detected using a Waters 740 UV detector at 254nm. An internal standard, S-adenosylethionine, was added to all samples and standard solutions to a concentration of 100μM.

Measurement of Intracellular TG Content

To determine the intracellular TG content, HepG2 cells seeded in 24-well plates were washed twice with phosphate buffered saline (PBS) and cellular lipids were extracted by 1ml hexane:isopropanol (3:2) mixture. TG content was measured using a TG assay kit (Infinity, Thermo Electron, Melbourne, Australia). Cells undergoing the same treatment conditions were lysed in RIPA buffer for protein concentration determination and data normalization.

Suppression of DGAT2 Expression by Small Interfering RNA (siRNA)

RNA targeting the human DGAT2 gene and a control siRNA containing a scrambled sequence (Ambion, Austin, TX) were transfected by siPORT™ NeoFX™ Transfection Agent (Ambion, Austin, TX), according to the manufacturer's instructions.

Measurement of DGAT2 Activity

The microsomal fraction from HepG2 cells was prepared as described previously (38). Because DGAT2 activity is inhibited at high concentrations of MgCl₂ (100mM), the DGAT assay was carried out in the presence of 8mM and 100mM MgCl₂ and DGAT2 activity was calculated by subtracting the value obtained
at 100mM from the value obtained at 8mM. Brief, 200μl of the reaction mixture containing 200μM sn-1,2-dioleoylglycerol (Sigma-Aldrich, Saint Louis, MO) in acetone, 30μM [14C]oleoyl-CoA (American Radiolabeled Chemicals, Saint Louis, MO), 8mM MgCl₂, 200μg BSA, and 10μg microsomal protein in 175mM Tris-HCl buffer, pH 8.0 was incubated for 30 min at 25 °C. After incubation, the reaction was stopped by adding 1.5ml stop solution [2-propanol-heptane-water (80:20:2, v/v)]. The top heptane phase was collected and washed with alkaline ethanol. An aliquot of the top heptane phase was used for radioactivity measurements using a Beckman LS 5801 counter.

**Quantitative Real-time RT-PCR**

Total RNA, from either frozen liver tissue or cultured cells, was isolated with a phenol-chloroform extraction. For each sample, 1.0μg total RNA was reverse transcribed using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). The cDNA was amplified in MicroAmp Optical 96-well reaction plates with a SYBR Green PCR Master Mix (Applied Biosystems) on an Applied Biosystems Prism 7000 sequence detection system. Relative gene expression was calculated after normalization by a house-keeping gene (mouse or human 18S rRNA).

**Western Blotting**

Liver tissues were homogenized and HepG2 cells were lysed in RIPA buffer and the isolated proteins were separated by SDS polyacrylamide gel electrophoresis and transferred to 0.45μm polyvinylidene difluoride membrane. After transfer, membranes were blocked in 5% bovine serum albumin in PBS with 0.1% Tween 20 and probed with anti-DGAT2 (Novus Biologicals, Littleton, CO), anti-SREBP-1c (Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho-ERK1/2 or anti-ERK1/2 (Cell Signaling Technology, Danvers, MA) antibodies. Horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence substrate kit were used in detection of specific proteins.

**Statistical Analysis**
All data are expressed as means ± SD. Statistical analysis was performed using a one-way ANOVA and further analyzed by Newman-Keuls test for statistical difference. Differences between treatments were considered to be statistically significant at P < 0.05.
RESULTS

Chronic Alcohol Exposure Increased Hepatic DGAT2 Gene Expression and Protein Production

Chronic alcohol consumption for 4 weeks caused fatty liver and liver injury, as evidenced by significantly increased plasma ALT levels, increased liver weight vs. body weight ratio, and elevated liver TG content in the alcohol-fed group (data not shown). Long-term AF increased DGAT2 gene (Fig. 1A) and protein expression (Fig. 1B & C) in the liver when compared with the PF group. We also examined the effect of AF on hepatic expression of sterol regulatory element binding protein-1c (SREBP-1c), the master regulator of de novo FA synthesis. In line with previous studies (21-23), AF significantly elevated SREBP-1c protein in the liver (Fig. 1D & E).

Chronic Alcohol Exposure Resulted in ERK1/2 Suppression in the Liver

To examine the effect of AF on MAPK activation in the liver, we conducted immunoblotting analysis using total liver tissue extracts from both PF and AF mice. As shown in Figure 2, AF had no effect on JNK activation (Fig. 2A), while the activation of p38 was minimally enhanced (Fig. 2B). However, AF resulted in a significant reduction in the phosphorylation of ERK1/2 (Fig. 2C & D), which was in line with our previous observation in rats (19). No changes in protein levels of the three members of the MAPK family were observed in the liver of AF animals when compared with PF controls.

Chronic Alcohol Exposure Caused Abnormal Methionine Metabolism in the Liver

To determine the effects of AF on methionine metabolism in the liver, we measured SAM, SAH, betaine, and glutathione (GSH) concentrations in the liver via HPLC. In line with our previous reports, AF significantly decreased hepatic SAM levels, while hepatic SAH levels were significantly elevated, leading to a significantly decreased SAM/SAH ratio. Liver betaine levels decreased slightly in AF, while GSH levels in the liver significantly decreased (table 1).

MEK/ERK1/2 Inhibition Leads to Increased Intracellular TG Accumulation in Hepatocytes
To determine if ERK1/2 inhibition was associated with increased TG accumulation in the liver, we treated HepG2 cells with two specific inhibitors of the MEK/ERK1/2 pathway, U0126 (10μM) and PD98059 (10μM), before challenging cells with oleic acid. Intracellular TG levels were assayed 20 hours later. As shown in Fig. 3, both inhibitors significantly increased intracellular TG content (Fig. 3A). To examine whether TG accumulation could be prevented by enhancing ERK1/2 activation, we treated HepG2 cells with EGF (100ng/ml), an activator of ERK1/2 signaling, prior to oleic acid challenge. EGF treatment reduced intracellular TG content (Fig. 3B), which was associated with enhanced ERK1/2 activation (Fig. 3C).

**MEK/ERK1/2 Suppression Upregulated DGAT2 expression and activity in HepG2 Cells**

To test whether hepatic ERK1/2 inhibition affected DGAT2 expression, gene and protein expression and DGAT2 activity were measured. Exposure to the ERK1/2 inhibitor U0126 (10μM) resulted in an approximate 5-fold increase in DGAT2 mRNA expression in HepG2 cells compared with the untreated group (Fig. 3D). In contrast, enhanced ERK1/2 activation by EGF (100ng/ml) decreased DGAT2 mRNA levels (Fig. 3E). Moreover, exposure of cells to U0126 to inhibit ERK1/2 activation significantly increased DGAT2 enzymatic activity (Fig. 3F). Furthermore, transfection of HepG2 cells with DGAT2 siRNA, which caused an 80% decrease in DGAT2 mRNA expression, significantly decreased intracellular TG levels (Fig. 4A & B). Accordingly, treatment with DGAT2 siRNA completely prevented U0126-induced intracellular TG increase in HepG2 cells (Fig. 4B), implying that upregulation of DGAT2 contributes to the increased hepatic TG content by ERK1/2 inhibition.

**Inhibition of Methyltransferase Suppressed MEK/ERK1/2 Activation, Enhanced DGAT2 Expression, and Elevated TG Contents in HepG2 Cells**

In order to determine whether inhibition of transmethylation reactions was related with hepatic ERK1/2 inhibition and DGAT2 induction, we applied N-acetyl-S-farnesyl-L-cysteine (AFC), an inhibitor of
SAM-dependent methyltransferases (specific for isoprenylcysteine carboxyl methyltransferase, ICMT), to HepG2 cells. Result showed that treatment with AFC (from 10μM to 40μM) for 24 hours decreased ERK1/2 phosphorylation in a dose-dependent fashion (Fig. 5A). In addition, AFC significantly augmented intracellular TG levels (Fig. 5B) and DGAT2 gene expression (Fig. 5C) when compared with the untreated group.

The Beneficial Effect of Betaine in ALD was Associated with Improved Methionine Metabolism, Alleviated ERK1/2 Inhibition, and Attenuated DGAT2 Induction in the Liver

Betaine exerts beneficial effects on fatty liver diseases by improving methionine metabolism. In an attempt to elucidate the mechanisms for the beneficial effect of betaine in ALD, betaine, at a dose of 1% (v/w), was supplemented in the alcohol-containing liquid diet. Four weeks later, we found that betaine supplementation prevented alcohol-induced fatty liver and liver injury, as evidenced by lowered TG content in the liver (Fig. 6A) and ALT levels in plasma (Fig. 6B), which were associated with significantly improved hepatic methionine metabolism (Table 1). Data showed that the beneficial effect of betaine supplementation was associated with alleviated ERK1/2 inhibition and attenuated DGAT2 induction (Fig. 6C-E) in the liver.
DISCUSSION

Neutral fat (mainly TG) deposition is the initial stage of alcoholic fatty liver disease and plays a critical role in disease progression. Although the exact mechanisms remain elusive, it is generally accepted that increased hepatic de novo FA synthesis plays a critical role in the development of fatty liver. FA synthesis is centrally regulated by SREBP-1c, a nuclear transcription factor, via a subset of enzymes involved in de novo FA synthesis, including acetyl-coA carboxylase (ACC), fatty acid synthase (FAS), and stearoyl-CoA desaturase (SCD). Enhanced gene expression and transactivation of SREBP-1c in the liver and subsequently increased hepatic de novo FA synthesis by AF have been documented by several groups (21-23). However, the effects of alcohol consumption on the downstream steps in TG synthesis remain unclear. TG is synthesized from three FA and glycerol through ester bonds. Among the complex metabolism network for TG synthesis in the liver, DGAT is a rate-limiting enzyme catalyzing the final step in TG synthesis by facilitating the linkage of sn-1,2-diacylglycerol with a long chain fatty acyl-CoA. Overexpression of DGAT2 is associated with hepatic steatosis (7); suppression of DGAT2 with antisense oligonucleotides reverses diet-induced hepatic steatosis (8-10), suggesting that DGAT2 exerts an important role in the development of fatty liver diseases. The present study provides initial evidence showing that chronic alcohol consumption induces expression of DGAT2 at both the gene and protein level. Since FA for TG synthesis in the liver derives not only from endogenous de novo lipogenesis but also exogenous sources (e.g., dietary fat or white adipose tissue via lipolysis during fasting), it is conceivable that upregulation of DGAT2 by chronic alcohol consumption may play an important role in the development of alcohol-induced hepatic steatosis.

ERK1/2-regulated pathways play an important role in controlling lipid metabolism in the liver (24, 25). We and others previously reported that chronic alcohol exposure causes significant MEK/ERK1/2 suppression in the liver (19, 31, 32). In the present study, we demonstrate that alcohol-induced hepatic MEK/ERK1/2 suppression is associated with increased DGAT2 expression and protein production. In vitro
studies reveal that specific inhibition of MEK/ERK1/2 activation increases gene expression and enzymatic activity of DGAT2 in HepG2 cells and causes intracellular TG accumulation. Conversely, enhanced ERK1/2 activation through EGF stimulation, slightly but significantly suppresses DGAT2 gene expression and prevents intracellular TG accumulation. Furthermore, our data show that elevation of intracellular TG content induced by MEK/ERK1/2 is inhibited by DGAT2 siRNA in HepG2 cells, indicating that DGAT2 upregulation contributes to increased TG synthesis by MEK/ERK1/2 inactivation. Since HepG2 cells have high N-ras activity, and thus high ERK1/2 activity (25, 26) compared with primary hepatocytes, it is conceivable that the decreased amplitude in DGAT2 gene expression by EGF in HepG2 cells was much less than the increased one triggered by ERK1/2 inhibitor U0126. Collectively, our data support the hypothesis that suppression of ERK1/2 activation by chronic alcohol exposure plays a critical role in up-regulating DGAT2 in the liver. Our study suggests that the hepatic MEK/ERK1/2 pathway may be a therapeutic target for treatment of ALD. Further support for this hypothesis derived from a study showing that EGF, a strong ERK1/2 activator, confers beneficial effects on alcohol-induced fatty liver and liver injury (27).

ERK1/2 is a member of the MAPK family, whose activation results in cell growth, proliferation, survival, and inflammation. The results with regard to the effect of alcohol exposure on ERK1/2 activation are controversial, mainly due to the cell type usage and exposure duration. For instance, accumulating evidence indicates that chronic alcohol exposure activates the MEK/ERK1/2 pathway and potentiates endotoxin-stimulated ERK1/2 activation in Kupffer cells, resulting in increased synthesis of tumor necrosis factor and augmented inflammatory responses (28, 29). It has also been well documented that acute exposure to alcohol results in modest activation of ERK1/2 in hepatocytes (30), whereas chronic alcohol exposure suppresses both constitutive and growth factor-stimulated ERK1/2 activation in the liver (31-32). The mechanisms involved in MEK/ERK1/2 inhibition by chronic alcohol exposure are not well understood
and are probably multifactorial. The ethanol-induced lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) has been reported to be an upstream modulator of ERK1/2 activation (31). Inhibition of the insulin receptor substrate 1 (IRS-1) signaling pathway by chronic alcohol consumption may also contribute to suppressed ERK1/2 activation in the liver (32). The Ras/Raf/MEK/ERK1/2 pathway is the major signal transduction pathway for ERK1/2 activation, which is strongly dependent on the GTPase Ras, whose activity requires its association with cellular membranes (17, 18). Ras plasma membrane association requires a series of posttranslational modifications of its carboxyl terminus, including farnesylation, proteolysis, and methylation of its CAAX sequence. These modifications allow CAAX proteins to associate with cellular membranes and promote protein–protein interactions (33). The methylation reactions require SAM as a methyl group donor to produce methylated Ras, thus linking methionine metabolism to modulation of MEK/ERK1/2 activation. Indeed, intracellular SAH level is negatively related to ICMT activity (34). In addition, 3-Deazaadenosine, a potent inhibitor of S-adenosylhomocysteine hydrolase, whose inhibition induces intracellular SAH accumulation, prevents vascular smooth muscle cell proliferation and neointima formation by interfering with Ras methylation and thereby with mitogenic activation of ERK1/2 (35). Abnormalities in hepatic methionine metabolism are well documented in ALD. Decreased phosphatidylethanolamine methyltransferase (PEMT) activity due to disrupted transmethylation reactions and subsequently decreased phosphatidylcholine synthesis contributes to alcohol-induced fatty liver via suppressing VLDL formation and secretion. In agreement with this observation, improvement of methionine metabolism by betaine supplementation alleviates PEMT suppression and attenuates alcoholic fatty liver (36). In line with previous studies, our results show that chronic alcohol exposure is associated with suppressed hepatic transmethylation reactions, evidenced by decreased SAM and increased SAH levels in the liver, leading to a significantly decreased SAM:SAH ratio. In the present study we examined whether inhibition of methylation reactions could also modulate ERK1/2 activation in hepatocytes by treating
HepG2 cells with AFC, a specific inhibitor of ICMT. Our results demonstrate that AFC exposure leads to ERK1/2 inhibition, which is associated with increased DGAT2 expression and elevated intracellular TG accumulation. Since ICMT is the methyltransferase specifically involved in posttranslational modification of Ras protein, these results suggest that ERK1/2 inhibition is a mechanistic link between abnormal methionine metabolism and DGAT2 upregulation in the liver. These observations also imply that the beneficial effects of betaine and folate supplementation in ALD may result from their ability to activate ERK1/2 and thereby attenuate DGAT2 upregulation by improving hepatic methionine metabolism. This is indeed validated by our study with betaine supplementation, in which we found that betaine supplementation improves liver injury and hepatic fat accumulation in AF mice, in parallel with improved methionine metabolism, alleviated hepatic ERK1/2 suppression, and attenuated hepatic DGAT2 overexpression.

Hepatic lipid metabolism is complex and dynamically regulated. Excessive TG accumulation in the liver originates from an imbalance between TG synthesis and removal via mitochondrial beta-oxidation and VLDL secretion. In line with previous reports (21-23), in this study we demonstrate increased SREBP-1c protein abundance in the liver of AF mice (Fig 3D & E), an indication of enhanced de novo FA synthesis. Moreover, increased plasma FA levels suggest that FA from adipose tissue lipolysis contributes to the intrahepatic FA pool for TG synthesis. Although in the present study we did not directly measure the effect of chronic alcohol exposure on VLDL secretion and mitochondrial beta-oxidation of FA, elevated plasma ketone bodies and fasting TG concentrations in AF mice provide indirect evidence of enhanced FA oxidation and VLDL secretion in the early stages of ALD. The elevated plasma TG content is in line with the observed hepatic DGAT1 expression (data not shown), which plays an important role in VLDL secretion (37). These data altogether suggest that both TG synthesis and disposal are enhanced in the early stage of alcoholic liver disease and that fatty liver develops when the capability of the liver to remove TG dose not compensate for
the increased synthesis.

In conclusion, we demonstrate that upregulation of hepatic DGAT2 by chronic alcohol exposure contributes to the development of ALD. Abnormal hepatic methionine metabolism, specifically the suppression of transmethylation reactions, plays a mechanistic role in alcohol-induced DGAT2 upregulation by suppressing MEK/ERK1/2 activation. Therefore, inhibition of ERK1/2 activation represents a critical link between methionine metabolism and fatty liver development via upregulation of hepatic DGAT2 expression.

Acknowledgments: We thank Dr. Alan Diamond from the Department of Pathology, Dr. P. V. Subbaiah from the Department of Medicine, and Dr. Giamila Fantuzzi from the Department of Kinesiology and Nutrition for their technical support, scientific advice, and generous editorial assistance.
REFERENCES


Fig. 1. Chronic alcohol exposure increased hepatic DGAT2 gene expression and protein production. Male C57BL/6 mice were pair-fed liquid diets with or without ethanol for 4 weeks. Chronic alcohol exposure increased DGAT2 gene expression (A) and protein abundance (B) in the liver. (C) Quantitative analysis of DGAT2 protein in the liver, normalized by corresponding GAPDH expression level. (D) The protein abundance of SREBP-1c in the liver was augmented significantly in alcohol-fed mice; (E) quantitative analysis of SREBP-1c protein expression in the liver, normalized by corresponding actin expression level. Data are means ± SD (n = 4). * P < 0.05. PF: pair-fed; AF: alcohol-fed.

Fig. 2. Chronic alcohol exposure resulted in prominent ERK1/2 suppression in the liver. Male C57BL/6 mice were pair-fed liquid diets with or without ethanol for 4 weeks. Chronic alcohol exposure had no effect on JNK activation (A) and minimally enhanced p38 activation (B) in the liver. (C) Chronic alcohol exposure decreased the phosphorylation levels of ERK1/2 in the liver; (D) quantitative analysis of ERK1/2 phosphorylation in the liver, normalized by corresponding total ERK1/2 expression level. Data are means ± SD (n = 4). * P < 0.05. PF: pair-fed; AF: alcohol-fed.

Fig. 3. MEK/ERK1/2 inhibition leads to increased intracellular TG accumulation in hepatocytes. HepG2 cells were pre-treated with MEK/ERK1/2 inhibitors or activator for 2 hours, and then challenged with 0.3mM oleic acids for 20 hours. (A) MEK/ERK1/2 inhibitors, U0126 (10μM) or PD98059 (10μM), elevated intracellular TG content; while (B) EGF (100ng/ml), an activator of ERK1/2 signaling, reduced intracellular TG content in HepG2 cells. (C) The time course for the effect of EGF on ERK1/2 activation. HepG2 cells were treated with EGF (100ng/ml) and cell lysates were collected at different time points. ERK1/2 activation was measured by detecting its phosphorylation. On the other hand, HepG2 cells were treated with U0126 (10μM) or EGF (100ng/ml) for 18 hours, then the total RNA was isolated and DGAT2 gene expression was analyzed by real time RT-PCR. (D) U0126 enhanced gene expression of DGAT2; conversely, (E) EGF inhibited the gene expression of DGAT2 in HepG2 cells. Further, the microsomes in HepG2 cells between untreated group and U0126-treated group were isolated for determining the DGAT2 activity. (F) Application of U0126 to inhibit ERK1/2 activation elevated the DGAT2 activity significantly in HepG2 cells. All values are denoted as means ± SD from three or more independent batches of cells, *P < 0.05.
Fig. 4. DGAT2 silencing prevented the elevation of TG content caused by MEK/ERK1/2 suppression in HepG2 cells. Transfection of siRNA for DGAT2 into HepG2 cells decreased DGAT2 mRNA levels (A), which prevented U0126 (10μM)-induced intracellular TG elevation (B). All values were denoted as means ± SD from three or more independent batches of cells, *P < 0.05.

Fig. 5. Inhibition of methyltransferases suppressed MEK/ERK activation, enhanced DGAT2 expression, and elevated TG contents in HepG2 cells. (A) AFC suppressed the phosphorylation level of ERK1/2. HepG2 cells were treated with methyltransferases inhibitor AFC (10μM, 20μM or 40μM) for 24 hours and cell lysates were collected for detecting ERK1/2 phosphorylation. (B) AFC increased the intracellular TG content. HepG2 cells were pre-treated with AFC (40μM) for 2 hours before challenged with 0.3mM oleic acids. Intracellular TG contents were measured 20 hours later. (C) AFC decreased the gene expression of DGAT2 in HepG2 cells. HepG2 cells were treated with AFC (40μM) for 18 hours and total RNA was isolate and DGAT2 gene expression was determined by real time RT-PCR. All values were denoted as means ± SD from three or more independent batches of cells, *P < 0.05.

Fig. 6. Betaine supplementation alleviated alcohol-induced ERK1/2 inhibition and DGAT2 induction in the liver. Male C57BL/6 mice were fed alcohol-containing liquid diets (AF) with or without betaine [1% (wt/vol)] supplementation for 4 weeks. (A) Liver TG contents; (B) Plasma ALT levels; (C) Betaine supplementation attenuated alcohol-induced ERK1/2 inhibition and DGAT2 induction in the liver. Data are means ± SD (n = 4). (D) Quantitative analysis of ERK1/2 phosphorylation in the liver, normalized by corresponding total ERK1/2 expression level. (E) Quantitative analysis of DGAT2 expression in the liver, normalized by corresponding actin expression level. Data are means ± SD (n = 4). *p< 0.05. AF: alcohol-fed; BT: betaine.
<table>
<thead>
<tr>
<th></th>
<th>PF</th>
<th>AF</th>
<th>AF+BT</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAM (nmol/g liver)</td>
<td>172.25 ± 15.95</td>
<td>115.93 ± 36.04*</td>
<td>221.33 ± 36.69#</td>
</tr>
<tr>
<td>SAH (nmol/g liver)</td>
<td>69.75 ± 8.62</td>
<td>219.33 ± 94.36*</td>
<td>175.67 ± 51.40*</td>
</tr>
<tr>
<td>SAM/SAH</td>
<td>2.48 ± 0.08</td>
<td>0.63 ± 0.35*</td>
<td>1.30 ± 0.25*#</td>
</tr>
<tr>
<td>Betaine (mg/g liver)</td>
<td>6.74 ± 1.11</td>
<td>4.89 ± 2.05</td>
<td>18.87 ± 8.76*#</td>
</tr>
<tr>
<td>GSH (mmol/g liver)</td>
<td>4.66 ± 0.10</td>
<td>3.93 ± 0.22*</td>
<td>4.49 ± 0.19#</td>
</tr>
</tbody>
</table>

Data represent mean ± SD (N=4).

Abbreviation: PF, pair-fed; AF, alcohol-fed; BT, betaine.

*P < 0.05 compared with PF, *P < 0.05 compared with AF.
Figure 1

A

![Bar chart showing relative mRNA levels of DGAT2 in PF and AF samples.]

B

![Western blot showing DGAT2 and GAPDH protein levels in PF and AF samples.]

C

![Bar chart showing relative value of DGAT2 in PF and AF samples.]

D

![Western blot showing SREBP1 and Actin protein levels in PF and AF samples.]

E

![Bar chart showing relative value of SREBP-1c in PF and AF samples.]

Abbreviations: PF, control; AF, experimental group.

*Significant difference compared to control group.
Figure 2

A  
\[ \text{pJNK, JNK, GAPDH} \]

B  
\[ \text{pP38, P38, GAPDH} \]

C  
\[ \text{pERK1/2, ERK1/2, GAPDH} \]

D  
\[ \text{ERK phosphorylation vs. PF, AF} \]

* indicates significant difference.
Figure 3

A

TG levels (% relative to the untreated)

<table>
<thead>
<tr>
<th></th>
<th>UT</th>
<th>U0126</th>
<th>PD98059</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>0.5</td>
<td>5</td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>24</td>
<td>6</td>
<td>12</td>
<td>18</td>
</tr>
</tbody>
</table>

B

TG levels (% relative to the untreated)

<table>
<thead>
<tr>
<th></th>
<th>UT</th>
<th>EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>0.5</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>24</td>
<td>6</td>
<td>12</td>
</tr>
</tbody>
</table>

C

EGF (100 ng/ml)

<table>
<thead>
<tr>
<th></th>
<th>0.5</th>
<th>1</th>
<th>2</th>
<th>8</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phospho-ERK1/2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total-ERK1/2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D

Relative mRNA

<table>
<thead>
<tr>
<th></th>
<th>UT</th>
<th>U0126</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>0.5</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>7</td>
</tr>
</tbody>
</table>

E

Relative mRNA

<table>
<thead>
<tr>
<th></th>
<th>UT</th>
<th>EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>0.5</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

F

DGAT2 Activity (% increase)

<table>
<thead>
<tr>
<th></th>
<th>UT</th>
<th>U0126</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>150</td>
</tr>
<tr>
<td>0.5</td>
<td>200</td>
<td>300</td>
</tr>
<tr>
<td>1</td>
<td>300</td>
<td>450</td>
</tr>
<tr>
<td>2</td>
<td>450</td>
<td>750</td>
</tr>
</tbody>
</table>

* indicates statistical significance.
Figure 5

A

<table>
<thead>
<tr>
<th></th>
<th>UT</th>
<th>AFC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

pERK1/2
ERK1/2
GAPDH

B

C

**TG levels (% relative to the untreated)**

**Relative mRNA**

UT  AFC  UT  AFC

*
Figure 6

A

Hepatic Triglyceride (mg/g liver)

AF  AF+BT

B

Plasma ALT (IU/L)

AF  AF+BT

C

pERK1/2

ERK1/2

DGAT2

Actin

AF  AF + BT

D

ERK phosphorylation

AF  AF+BT

E

DGAT2

AF  AF+BT

* indicates statistical significance